Combination Therapy of Inhaled Indacaterol/Glycopyrronium for Chronic Obstructive Pulmonary Disease in the Very Elderly: Is It Safe? An Electrocardiographic Evaluation

Francesco Spannella, Federico Giulietti, Valentina Cesari, Antonio Francioso, Guido Cocci, Laura Landi, Francesca Elena Lombardi, Elisabetta Borioni, Beatrice Bernardi, Giulia Rosettani, Valentina Bordoni, Corrado Iacoacci, Piero Giordano, Riccardo Sarzani

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Cardiovascular (CV) comorbidities in patients with chronic obstructive pulmonary disease (COPD) are associated with increased morbidity and mortality, especially in old and very old subjects. The question if long-acting beta-agonist and long-acting muscarinic antagonist could be associated with the increased prevalence of CV-related adverse effects has puzzled, particularly in the past, specialists involved in the management of respiratory diseases. The safety of these compounds has scarcely been tested in patients aged ≥ 65 years with CV comorbidities, since randomized controlled trials rarely include this subpopulation. However, the fixed combination indacaterol/glycopyrronium has shown a favorable CV safety profile in both healthy volunteers and COPD patients. Thus, we aimed to assess the CV safety pro<X00-Del-TrennDivis> - </X00-Del-TrennDivis> file of the fixed combination indacaterol/glycopyrronium 110/50 μg in a series of COPD patients aged ≥ 80 years with several comorbidities. Our results indicate that this combination is safe in the comorbid elderly, since no significant electrocardiographic abnormalities were recorded after the administration of the inhaled therapy. Only rare and nonclinically significant changes in heart rate and corrected QT interval duration were evident, mainly in females and in patients with concomitant impaired kidney function.

Original languageEnglish
Pages (from-to)22-29
Number of pages8
JournalRespiration
Volume95
DOIs
Publication statusPublished - Apr 1 2018

Fingerprint

Chronic Obstructive Pulmonary Disease
Comorbidity
Safety
Therapeutics
Muscarinic Antagonists
Disease Management
Healthy Volunteers
Randomized Controlled Trials
Heart Rate
indacaterol
Morbidity
Kidney
Mortality

Keywords

  • Chronic obstructive pulmonary disease
  • Elderly
  • Indacaterol/glycopyrronium

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Combination Therapy of Inhaled Indacaterol/Glycopyrronium for Chronic Obstructive Pulmonary Disease in the Very Elderly : Is It Safe? An Electrocardiographic Evaluation. / Spannella, Francesco; Giulietti, Federico; Cesari, Valentina; Francioso, Antonio; Cocci, Guido; Landi, Laura; Lombardi, Francesca Elena; Borioni, Elisabetta; Bernardi, Beatrice; Rosettani, Giulia; Bordoni, Valentina; Iacoacci, Corrado; Giordano, Piero; Sarzani, Riccardo.

In: Respiration, Vol. 95, 01.04.2018, p. 22-29.

Research output: Contribution to journalArticle

Spannella, F, Giulietti, F, Cesari, V, Francioso, A, Cocci, G, Landi, L, Lombardi, FE, Borioni, E, Bernardi, B, Rosettani, G, Bordoni, V, Iacoacci, C, Giordano, P & Sarzani, R 2018, 'Combination Therapy of Inhaled Indacaterol/Glycopyrronium for Chronic Obstructive Pulmonary Disease in the Very Elderly: Is It Safe? An Electrocardiographic Evaluation', Respiration, vol. 95, pp. 22-29. https://doi.org/10.1159/000487182
Spannella, Francesco ; Giulietti, Federico ; Cesari, Valentina ; Francioso, Antonio ; Cocci, Guido ; Landi, Laura ; Lombardi, Francesca Elena ; Borioni, Elisabetta ; Bernardi, Beatrice ; Rosettani, Giulia ; Bordoni, Valentina ; Iacoacci, Corrado ; Giordano, Piero ; Sarzani, Riccardo. / Combination Therapy of Inhaled Indacaterol/Glycopyrronium for Chronic Obstructive Pulmonary Disease in the Very Elderly : Is It Safe? An Electrocardiographic Evaluation. In: Respiration. 2018 ; Vol. 95. pp. 22-29.
@article{7d4823439ab547c99d02ce373c616b70,
title = "Combination Therapy of Inhaled Indacaterol/Glycopyrronium for Chronic Obstructive Pulmonary Disease in the Very Elderly: Is It Safe? An Electrocardiographic Evaluation",
abstract = "Cardiovascular (CV) comorbidities in patients with chronic obstructive pulmonary disease (COPD) are associated with increased morbidity and mortality, especially in old and very old subjects. The question if long-acting beta-agonist and long-acting muscarinic antagonist could be associated with the increased prevalence of CV-related adverse effects has puzzled, particularly in the past, specialists involved in the management of respiratory diseases. The safety of these compounds has scarcely been tested in patients aged ≥ 65 years with CV comorbidities, since randomized controlled trials rarely include this subpopulation. However, the fixed combination indacaterol/glycopyrronium has shown a favorable CV safety profile in both healthy volunteers and COPD patients. Thus, we aimed to assess the CV safety pro<X00-Del-TrennDivis> - file of the fixed combination indacaterol/glycopyrronium 110/50 μg in a series of COPD patients aged ≥ 80 years with several comorbidities. Our results indicate that this combination is safe in the comorbid elderly, since no significant electrocardiographic abnormalities were recorded after the administration of the inhaled therapy. Only rare and nonclinically significant changes in heart rate and corrected QT interval duration were evident, mainly in females and in patients with concomitant impaired kidney function.",
keywords = "Chronic obstructive pulmonary disease, Elderly, Indacaterol/glycopyrronium",
author = "Francesco Spannella and Federico Giulietti and Valentina Cesari and Antonio Francioso and Guido Cocci and Laura Landi and Lombardi, {Francesca Elena} and Elisabetta Borioni and Beatrice Bernardi and Giulia Rosettani and Valentina Bordoni and Corrado Iacoacci and Piero Giordano and Riccardo Sarzani",
year = "2018",
month = "4",
day = "1",
doi = "10.1159/000487182",
language = "English",
volume = "95",
pages = "22--29",
journal = "Respiration; international review of thoracic diseases",
issn = "0025-7931",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Combination Therapy of Inhaled Indacaterol/Glycopyrronium for Chronic Obstructive Pulmonary Disease in the Very Elderly

T2 - Is It Safe? An Electrocardiographic Evaluation

AU - Spannella, Francesco

AU - Giulietti, Federico

AU - Cesari, Valentina

AU - Francioso, Antonio

AU - Cocci, Guido

AU - Landi, Laura

AU - Lombardi, Francesca Elena

AU - Borioni, Elisabetta

AU - Bernardi, Beatrice

AU - Rosettani, Giulia

AU - Bordoni, Valentina

AU - Iacoacci, Corrado

AU - Giordano, Piero

AU - Sarzani, Riccardo

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Cardiovascular (CV) comorbidities in patients with chronic obstructive pulmonary disease (COPD) are associated with increased morbidity and mortality, especially in old and very old subjects. The question if long-acting beta-agonist and long-acting muscarinic antagonist could be associated with the increased prevalence of CV-related adverse effects has puzzled, particularly in the past, specialists involved in the management of respiratory diseases. The safety of these compounds has scarcely been tested in patients aged ≥ 65 years with CV comorbidities, since randomized controlled trials rarely include this subpopulation. However, the fixed combination indacaterol/glycopyrronium has shown a favorable CV safety profile in both healthy volunteers and COPD patients. Thus, we aimed to assess the CV safety pro<X00-Del-TrennDivis> - file of the fixed combination indacaterol/glycopyrronium 110/50 μg in a series of COPD patients aged ≥ 80 years with several comorbidities. Our results indicate that this combination is safe in the comorbid elderly, since no significant electrocardiographic abnormalities were recorded after the administration of the inhaled therapy. Only rare and nonclinically significant changes in heart rate and corrected QT interval duration were evident, mainly in females and in patients with concomitant impaired kidney function.

AB - Cardiovascular (CV) comorbidities in patients with chronic obstructive pulmonary disease (COPD) are associated with increased morbidity and mortality, especially in old and very old subjects. The question if long-acting beta-agonist and long-acting muscarinic antagonist could be associated with the increased prevalence of CV-related adverse effects has puzzled, particularly in the past, specialists involved in the management of respiratory diseases. The safety of these compounds has scarcely been tested in patients aged ≥ 65 years with CV comorbidities, since randomized controlled trials rarely include this subpopulation. However, the fixed combination indacaterol/glycopyrronium has shown a favorable CV safety profile in both healthy volunteers and COPD patients. Thus, we aimed to assess the CV safety pro<X00-Del-TrennDivis> - file of the fixed combination indacaterol/glycopyrronium 110/50 μg in a series of COPD patients aged ≥ 80 years with several comorbidities. Our results indicate that this combination is safe in the comorbid elderly, since no significant electrocardiographic abnormalities were recorded after the administration of the inhaled therapy. Only rare and nonclinically significant changes in heart rate and corrected QT interval duration were evident, mainly in females and in patients with concomitant impaired kidney function.

KW - Chronic obstructive pulmonary disease

KW - Elderly

KW - Indacaterol/glycopyrronium

UR - http://www.scopus.com/inward/record.url?scp=85046754992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046754992&partnerID=8YFLogxK

U2 - 10.1159/000487182

DO - 10.1159/000487182

M3 - Article

C2 - 29705783

AN - SCOPUS:85046754992

VL - 95

SP - 22

EP - 29

JO - Respiration; international review of thoracic diseases

JF - Respiration; international review of thoracic diseases

SN - 0025-7931

ER -